Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Get Free Report) shares shot up 13% on Wednesday after BTIG Research raised their price target on the stock from $18.00 to $20.00. BTIG Research currently has a buy rating on the stock. Brainsway traded as high as $16.95 and last traded at $16.93. Approximately 425,392 shares changed hands during trading, an increase of 159% from the average session volume of 164,121 shares. The stock had previously closed at $14.98.
BWAY has been the subject of a number of other research reports. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday, August 2nd. New Street Research restated a "buy" rating on shares of Brainsway in a research note on Friday, July 24th. HC Wainwright restated a "buy" rating and set a $14.00 price target on shares of Brainsway in a research report on Friday, July 17th. Zacks Research raised Brainsway from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 13th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of Brainsway in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $16.33.
Get Our Latest Stock Report on BWAY
Trending Headlines about Brainsway
Here are the key news stories impacting Brainsway this week:
- Positive Sentiment: BrainsWay reported record second-quarter 2026 revenue of $17.1 million, up 35% year over year and above analysts’ $16.54 million consensus. The results and operational highlights point to continued demand for the company’s Deep TMS platform. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
- Positive Sentiment: The company raised or reaffirmed a favorable outlook for fiscal 2026 revenue at $68 million to $70 million, modestly above the $67.8 million analyst consensus. This guidance suggests management expects growth to continue through the year. BrainsWay Q2 2026 Earnings Call Transcript
- Positive Sentiment: BTIG Research raised its price target for BWAY from $18 to $20 and assigned a “Buy” rating. The new target implies meaningful upside from the stock’s recent trading level and may reinforce investor confidence in the company’s growth prospects. BTIG Research price target update
- Neutral Sentiment: The earnings call and recent results provide additional details on BrainsWay’s commercial execution, profitability and 2026 outlook. Investors will likely focus on whether the company can convert strong revenue growth into consistent earnings expansion. BrainsWay Q2 2026 Earnings Call Transcript
- Negative Sentiment: Second-quarter EPS was $0.07, below the $0.10 consensus estimate. While net margin was 15.68% and return on equity was 12.28%, the earnings shortfall could limit enthusiasm, particularly with the stock trading at a relatively elevated forward valuation. BrainsWay second-quarter 2026 earnings release
Hedge Funds Weigh In On Brainsway
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ballast Advisors LLC acquired a new position in shares of Brainsway in the first quarter worth $55,000. Bank of America Corp DE purchased a new position in Brainsway in the first quarter valued at $206,000. Royal Bank of Canada boosted its holdings in Brainsway by 84.2% in the first quarter. Royal Bank of Canada now owns 15,490 shares of the company's stock valued at $206,000 after purchasing an additional 7,080 shares during the period. Masters Capital Management LLC grew its stake in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company's stock worth $21,928,000 after purchasing an additional 650,000 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company's stock worth $6,890,000 after purchasing an additional 241,560 shares during the period. Hedge funds and other institutional investors own 30.11% of the company's stock.
Brainsway Trading Up 14.5%
The company has a market cap of $688.25 million, a PE ratio of 49.00 and a beta of 1.24. The company has a fifty day simple moving average of $15.03 and a two-hundred day simple moving average of $14.30.
Brainsway (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The company had revenue of $17.11 million for the quarter, compared to analyst estimates of $16.54 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. On average, research analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current fiscal year.
About Brainsway
(
Get Free Report)
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Brainsway, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainsway wasn't on the list.
While Brainsway currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
